US2019151358A1PendingUtilityA1

P53 silenced endothelial progenitor cells for diabetes

56
Assignee: BAYSTATE HEALTH INCPriority: Apr 16, 2012Filed: Jun 26, 2018Published: May 23, 2019
Est. expiryApr 16, 2032(~5.8 yrs left)· nominal 20-yr term from priority
Inventors:Sabyasachi Sen
A61K 35/44A61K 35/14
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides, inter alia, methods for treating vascular deficiencies, including those in diabetic subjects, by transplanting endothelial progenitor cells with transiently reduced p53 expression.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 - 15 . (canceled) 
     
     
         16 . A composition comprising
 an endothelial progenitor cell genetically modified to have transiently reduced p53 expression for about 2-4 weeks.   
     
     
         17 . The composition of  claim 16 , wherein the endothelial progenitor cell is a CD34+ cell. 
     
     
         18 . The composition of  claim 17 , wherein the CD34+ cell is obtained from blood. 
     
     
         19 . The composition of  claim 17 , wherein the endothelial progenitor cell expresses p53-specific siRNA. 
     
     
         20 . The composition of  claim 19 , wherein the p53-specific siRNA is expressed from a non-integrating vector. 
     
     
         21 . The composition of  claim 19 , wherein the p53-specific siRNA is expressed from an adenovirus.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.